This guideline provides recommendations for medical laboratories and clinical practices that provide services for pain management.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Laboratory Support for Pain Management Programs

Catherine A. Hammett-Stabler, PhD, DABCC, FABC
Eveline S. Arnold, PhD
Justin Brower, PhD
William Clarke, PhD, MBA, DABCC, FABC
Patrice Donovan, MT
Robert L. Fitzgerald, PhD, DABCC, FABC
Loralie J. Langman, PhD, DABCC, FABC, F-ABFT

Gwendolyn A. McMillin, PhD, DABCC, FABC
Robert A. Middleberg, PhD, F-ABFT, DABCC
Nihmat Morjana, PhD, MSc
Michael Nicar, MS, PhD, C(ASCP)
Amadeo Pesce, PhD, DABCC
Sihe Wang, PhD, DABCC, FABC
Michelle Wood, PhD
Kiang-Teck J. Yeo, PhD, DABCC, FABC

Abstract

Clinical and Laboratory Standards Institute guideline C63—Laboratory Support for Pain Management Programs provides recommendations for medical laboratory toxicology-based testing services in support of the care and treatment of persons in pain management programs. This guideline discusses specimen types and collection, testing methodologies, and results reporting and interpretation. The intended users of this guideline include medical laboratory scientists and personnel, medical technologists, hospital administrators, physician office personnel, risk managers, pharmacists, and health care providers tasked with implementing pain management testing for their institutions or networks.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.
Contents

Abstract .................................................................................................................................................... i
Committee Membership ...................................................................................................................... iii
Foreword .............................................................................................................................................. vii

Chapter 1: Introduction ....................................................................................................................... 1
  1.1 Scope ........................................................................................................................................ 1
  1.2 Background ............................................................................................................................. 1
  1.3 Standard Precautions ............................................................................................................. 6
  1.4 Terminology ........................................................................................................................... 6

Chapter 2: Clinical Testing for Pain Management ............................................................................ 11
  2.1 Introduction to Pain Management Testing ........................................................................ 11
  2.2 Process Flow Chart .............................................................................................................. 11

Chapter 3: Specimen Types .............................................................................................................. 13
  3.1 Urine ......................................................................................................................................... 13
  3.2 Serum ....................................................................................................................................... 14
  3.3 Oral Fluid (Aqueous or Mucous Components) ..................................................................... 14
  3.4 Hair ......................................................................................................................................... 15

Chapter 4: Testing Methods .............................................................................................................. 17
  4.1 Screening Methods ................................................................................................................. 17
  4.2 Targeted Testing ..................................................................................................................... 24
  4.3 Quality Assurance for Targeted Testing ............................................................................. 27
  4.4 Validity Testing ....................................................................................................................... 27

Chapter 5: Results Reporting and Interpretation .............................................................................. 29
  5.1 Results Reporting ..................................................................................................................... 29
  5.2 Results Interpretation ............................................................................................................. 31

Chapter 6: Conclusion ....................................................................................................................... 38

Chapter 7: Supplemental Information ............................................................................................... 38
References ........................................................................................................................................ 39

Appendix. Detailed Information for Drug Testing Methodologies ................................................. 42
The Quality Management System Approach .................................................................................. 60
Related CLSI Reference Materials ................................................................................................. 61
Foreword

In the mid- to late 1990s, the health care industry recognized that many patients received inadequate pain management during hospitalization. In response, several initiatives evolved, making pain management a major focus of the health care industry and leading to the development of numerous services, clinics, and research efforts dedicated to pain management. Despite much progress in understanding acute and chronic pain mechanisms, pharmacotherapy using opiates and opioids remains the primary therapeutic intervention for patients with chronic pain. In addition, these patients often suffer from anxiety and depression, necessitating the use of anxiolytics and antidepressants.

Because pain management medications pose a risk of addiction and abuse, it is commonplace to monitor patients for compliance with therapy. Regrettably, some patients turn to illicit drugs, while others who are addicted to opioids attempt to acquire them by feigning pain, complicating this testing. To monitor patients, many facilities and providers rely on simple screening of a randomly collected urine specimen for a panel of drugs of abuse. Most often the screening method is immunoassay based and can include point-of-care devices for convenience. Unfortunately, immunoassays for urine drug testing vary considerably in specificity and sensitivity and are associated with both false-positive and false-negative results. These limitations are often poorly understood by health care providers outside the medical laboratory. Because confirmation of a positive screening result is neither practical nor mandated in the patient care setting, testing typically stops with screening. Similarly, an unexpected negative result might not receive additional scrutiny. Both situations have resulted in patients being accused of using nonprescribed drugs or not complying with the use of prescribed drugs and, in some cases, being dismissed from care. Recognizing the seriousness of these consequences, a growing number of laboratories are turning to mass spectrometry–based methods as the first line of testing and encouraging additional testing of any unexpected result, whether positive or negative. There is also growing interest in using alternate specimen types in specific situations. Thus, the needs of pain management services have changed the types of toxicology testing expected of medical laboratories, which have also encountered dramatic increases in testing requests. Laboratories have recognized the need to change testing menus and technologies, implement referral testing services, and find opportunities to interact more with providers who use their services.

This guideline provides recommendations for laboratory support of pain management clinics and services. Every effort has been made to present the state of toxicology testing for this area as it currently exists, recognizing that technological advances continued to change the testing landscape as this guideline was being written.

NOTE: The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

Key Words

Abused drugs, mass spectrometry, opiates, pain management, therapeutic drug monitoring, toxicology
Laboratory Support for Pain Management Programs

Chapter 1: Introduction

This chapter includes:

- Guideline’s scope and applicable exclusions
- Background information pertinent to the guideline’s content
- Standard precautions information
- “Note on Terminology” that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the guideline
- Abbreviations and acronyms used in the guideline

1.1 Scope

This guideline provides recommendations for laboratory support for pain management clinics and services, including guidance on specimen types and collection, testing methodologies, results reporting, and interpretation. To assist in results interpretation, this guideline includes several tables listing expected metabolites for commonly encountered drugs.

The intended users of this guideline include medical laboratory scientists and personnel, hospital administrators, physician office personnel, risk managers, pharmacists, and health care providers tasked with establishing pain management testing for their institutions or networks.

This guideline does not discuss in detail the pathophysiology or biochemistry of chronic pain, nor does it include information on dosing or prescribing of pain management drugs.

1.2 Background

Pain is an important aspect of life that often serves as a warning of injury. Most episodes of pain are acute and time limited, and they resolve with healing. Chronic pain, on the other hand, often evolves without a clear precipitating event and persists over a prolonged time, and its treatment is challenging. Surveys estimate that ~20% of individuals worldwide report chronic pain and that up to 75% of all individuals experience chronic pain at some point in their lives. Chronic pain is often comorbid with acute events and chronic diseases.1-3

Chronic pain treatment is often complex, involving psychological, social, and environmental interventions in addition to management of underlying diseases or pathology. Many patients become candidates for treatment at clinics specializing in pain management. These groups are typically multidisciplinary, involving a variety of physicians as well as other health care providers, such as nurses, pharmacists, laboratorys, nutritionists, and occupational therapists. The goal of treatment is to reduce the level of pain and improve the patient’s quality of life.

When non-narcotic analgesics and anti-inflammatories (eg, acetaminophen [paracetamol], ibuprofen, naproxen) fail, pharmacological treatment often involves the use of opiates and opioids. Muscle relaxants,
antidepressants, antiepileptics, sedatives, and topical anesthetics, some of which are controlled substances, are also commonly used and effective in many cases. Table 1 lists many drugs that are of interest in monitoring pain management patients.
The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system (QMS) approach in the development of standards and guidelines that facilitates project management, defines a document structure using a template, and provides a process to identify needed documents. The QMS approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are:

- Organization
- Personnel
- Process Management
- Nonconforming Event Management

- Customer Focus
- Purchasing and Inventory
- Documents and Records
- Assessments

- Facilities and Safety
- Equipment
- Information Management
- Continual Improvement

C63 covers the QSE indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section.

Path of Workflow

A path of workflow is the description of the necessary processes to deliver the particular product or service that the organization or entity provides. A laboratory path of workflow consists of the sequential processes: preexamination, examination, and postexamination and their respective sequential subprocesses. All laboratories follow these processes to deliver their services, namely quality laboratory information.

C63 covers the medical laboratory path of workflow processes indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section.
Sample